secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2021-12-20T23:59:59+00:00
Accession:  0001193125-21-362387
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam appoints Yvonne Greenstreet as CEO effective Jan 1, 2022; discloses compensation
--------------------------------------------------------------------------------

- Yvonne Greenstreet, formerly President and COO, becomes CEO on Jan 1, 2022.
- Annual base salary of $850,000; target bonus 100% of base salary for 2022 performance year.
- Initial equity: $5M stock option granting on Dec 31, 2021; additional $2.5M option and $7.5M PSUs in Feb 2022.
- $250,000 one-time relocation cash award with repayment obligation if termination for cause within 24 months.
- Severance: pre-Change-in-Control no cash severance but continued vesting for 2 years; post-CIC double trigger with 2x salary+bonus and full acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/0001193125-21-362387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/d163524d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-362387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer